drugset
drugset / Trial / NCT04950114

An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases

NCT04950114 ↗

Phase 2 Terminated 31 enrolled Goldfinch Bio, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label Phase 2 study evaluating the long term safety and tolerability of GFB-887 in patients with focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change disease (TR-MCD)

Timeline

Start
2021-07-27
Primary completion
2022-11-02
Completion
2022-11-02

Outcome

Outcome not reported

Stopped (Business): “Business reasons”

Drugs

EvaluationDrugModalityDoseRoute
Subject GFB-887 Small molecule 200 mg —

Indications

focal segmental glomerulosclerosis glomerulonephritis nephrosis